Saturday , January 20 2018
Home / Managing Editor, Diabetes in Control

Managing Editor, Diabetes in Control

Managing Editor, Diabetes in Control

DIC’s Most Popular Articles 2017

2017 was book-ended by the ADA: the new 2017 guidelines were the most popular article in January, and in December the 2018 guidelines took center stage. Please take a look back with us at everything that happened in between. We thank you for your readership this year, and look forward to sharing the important diabetes news of 2018.

Read More »

Survey Says: Your Thoughts in 2017

In 2017, we offered weekly survey questions on topics ranging from standard tests, to new drugs, to opinions on CGMs, to personal exercise habits - and you answered. Here are the survey questions that drew the most response this year.

Read More »

Name that Article

Can you name the one most-viewed DIC article in 2017? Your choices are: a) Health Benefits from Intermittent Fasting b) 1-Hour Post-Prandial Glucose Predicts Risk For Type 2 Diabetes c) New ADA 2017 Standards d) Type 1 Cured in Mice e)The Future For Insulin Pump Companies: Who Will Survive? Follow the link to see the correct answer!

Read More »

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #105: Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Part 3

Combined dietary intervention and exercise: The available information on the role of combined lifestyle interventions (hypocaloric diets plus exercise) in patients with NAFLD is much more extensive, with several randomized, controlled trials showing significant benefit with this comprehensive approach. Again, the overall reduction in liver fat reported in most of these trials has been strongly correlated with the amount of weight loss.

Read More »

The Next CGMS is the Senseonics Eversence System

Once given FDA approval, the Senseonics Eversence System will be the fourth CGMS available in the U.S. It was submitted to the FDA for premarket approval last October, supported by data from a 90-patient pivotal trial of the device. The trial followed adults with type 1 or type 2 diabetes over 90 days of CGM sensor wearing. This is an implantable CGM system that is currently approved in Europe. The sensor sits just under your skin and can stay there for anywhere from 90-180 days.

Read More »

Alzheimer’s Gene Linked to Diabetes

Researchers found that the Alzheimer’s gene ApoE4 could be linked to type 3 diabetes. The Apolipoprotein E (APOE) gene is one of the strongest genetic risk factors for Alzheimer’s disease. Diabetes and impaired insulin signaling in the brain are linked to the development of Alzheimer’s disease. This study shows how …

Read More »